Systemic Flaws in Trump's Drug Pricing Plan Exposed by Industry Reactions
Original framing: “STAT+: Pharmalittle: We’re reading about a Trump drug pricing flaw, a Gilead deal, and more” — STAT News
It draws on health‑services research showing that high prices depress adherence, increase mortality, and do not proportionally boost innovation. The analysis is grounded in peer‑reviewed data on cost‑effectiveness and R&D spending.
The Trump drug‑pricing proposal exposes a web of historical, cross‑cultural, and scientific contradictions that privilege corporate profit over public health.
By integrating Indigenous perspectives, transparent science, and future scenario planning, we can design systemic reforms—such as federal price negotiation and PBM restructuring—that center marginalized voices. A trickster lens reveals the policy's self‑defeating irony, urging a shift from market mythos to a holistic, equitable health economy.